Latest Insider Transactions at Rapport Therapeutics, Inc. (RAPP)
This section provides a real-time view of insider transactions for Rapport Therapeutics, Inc. (RAPP). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Rapport Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Rapport Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2025
|
David Bredt Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
8,500
-1.78%
|
$85,000
$10.85 P/Share
|
|
Mar 13
2025
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
100
+0.99%
|
$900
$9.98 P/Share
|
|
Mar 12
2025
|
Troy A. Ignelzi Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,900
+50.0%
|
$99,000
$10.1 P/Share
|
|
Mar 12
2025
|
Wendy B. Young |
BUY
Open market or private purchase
|
Direct |
6,000
+50.0%
|
$60,000
$10.21 P/Share
|
|
Mar 03
2025
|
Cheryl Gault Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,987
+7.52%
|
-
|
|
Jul 01
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
44,032
+10.4%
|
$1,056,768
$24.59 P/Share
|
|
Jun 10
2024
|
Arch Venture Partners Xii, LLC |
BUY
Conversion of derivative security
|
Indirect |
3,728,738
+50.0%
|
-
|
|
Jun 10
2024
|
Third Rock Ventures V, L.P. |
BUY
Conversion of derivative security
|
Indirect |
969,218
+50.0%
|
-
|
|
Jun 10
2024
|
Third Rock Ventures V, L.P. |
BUY
Conversion of derivative security
|
Direct |
6,551,449
+47.87%
|
-
|
|
Jun 10
2024
|
James Healy Director |
BUY
Open market or private purchase
|
Indirect |
558,824
+44.03%
|
$9,500,008
$17.0 P/Share
|
|
Jun 10
2024
|
James Healy Director |
BUY
Conversion of derivative security
|
Indirect |
1,392,738
+50.0%
|
-
|